Mei Ri Jing Ji Xin Wen·2025-04-07 01:17Group 1 - The innovative pharmaceutical industry is viewed positively as it is not currently affected by tariff policies, with opportunities for domestic market share growth in medical devices and blood products [1] - The Chinese medicine, pharmacies, and distribution sectors are less correlated with tariffs, focusing on domestic demand [1] - Long-term strategies for pharmaceutical companies should include international expansion, which is expected to bring incremental opportunities [1] Group 2 - The Hong Kong stock market is facing short-term pressure due to previous gains leading to higher valuations that need to be digested [2] - After the digestion of this pressure, there may be mid-term structural opportunities in sectors like information technology, healthcare, industrial, consumer, and finance, particularly for undervalued assets with fundamental support [2] Group 3 - Recent export controls on medium and heavy rare earths are expected to have a limited actual impact compared to theoretical estimates, as exports can still occur after approval [3] - The price dynamics of rare earths may diverge between domestic and international markets, with a higher likelihood of price increases abroad [3] - The strategic importance of rare earths as substitutes against tariff disruptions is emphasized, highlighting the need to focus on related stocks [3]